EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
There are a few things to report from EMA. Unfortunately, the EMA cannot join us as a president’s guest at Congress due to the measures that have been put in place for the pending move to Amsterdam. Every year, EAHP has to undergo an eligibility check. For 2018 we have passed this check and are consequently able to join all activities of EMA. The mandate of Adamos Hadjipanayis (European Academy of Paediatrics) has been extended. He will continue for the next 3 year as a member of the coordinating group of the European Network of Paediatric Research at the EMA (Enpr-EMA).
Review of the Biosimilar Medicines position paper
To be discussed under agenda item 11.7.1 on Saturday afternoon.
Commission event on Biosimilar Medicines – September 2018
On 7th September 2017 the Commission held its kick-off meeting for the next multi-stakeholder biosimilar workshop. A second meeting – during which the ideas for the 2018 Commission event on Biosimilars were discussed took place on 13th November 2017. Hilda Juhasz – the policy officer at the Commission responsible for this event – used this opportunity to introduce all stakeholders to her successor Chloé Spathari.
The 2018 event will take place on 14th September. 3 topics will be covered: oncology, education and procurement. EAHP is participating in the organisation of the procurement and the education session. Work for the procurement session is progressing much better than for the education session due to the smaller size of the organisation group. Europa Bio and Medicines for Europe are co-organisers of the procurement session, while in the education session there are ECCO, ESOP, ESNO, ESMO, Medicines for Europe and EONS.
Procurement session
We (EAHP, Europa Bio and Medicines for Europe) had several discussions with the Commission about the Procurement session. Overall, the Commission would like to have a mixed panel that showcases the sustainability of procurement. Scandinavian countries are not a good example in the eyes of the Commission since they did not implement the European procurement legislation as envisioned by the Commission (i.e. there should be less the winner takes it all procedures). Some issues remain open, since we are still looking for the following panellists:
Draft session outline HERE
Education session
The education session misses a few more panellists, since a lot of components are unknown (i.e. is the ESNO document on biosimilars ready, who will present the ESOP biosimilar curricular, which country should be selected to present national attitudes). A meeting/conference call is planned in early 2018 (no date has been set yet) to discuss the following open issues:
Draft session outline HERE
During the last Board meeting it was decided to start the development of a Procurement Position Paper. The field of procurement is quite large, wherefore we need to agree on a direction for our position paper. The following document (HERE) outlines ideas for our position paper.
HTA proposal
The European Commission is planning to publish a draft legislative proposal concerning HTA on 31st of January. The proposal is expected to focus on clinical aspects and the strengthening of cooperation between Member States. Overall, the proposal aims at addressing the issue of having multiple national assessments for the same products with sometimes different results for patients and industry. Moreover, it should address current challenges that a posed to health systems (i.e. ageing society, rapid increase of innovative medicines, cost effectiveness and accessibility). More information will be provided to the Board during the meeting.
The proposal has been published as expected. More information is available HERE
HTA Stakeholder Group
The HTA Stakeholder Group met in November 2017 to discuss coordination and cooperation. Meeting minutes HERE It was agreed that our permanent representative Daniel Widmer (UEMO) will be joined by either Piotor or Elena, as both have gathered the second largest number of votes in the selection exercise which was undertaken in March 2017. Elena has confirmed her availability. The group will get together again, once the HTA proposal by the Commission has been published.
In light of the Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU, Elena and Daniel have suggested to discuss the positions of each member of the stakeholder group prior to the next HTA meeting with the Commission which will take place on 9th February. Do we want to form an opinion on the proposal and if yes, shall I see with Gunar if he can provide me with comments by early next week?
